NZ703093A - Purification of iduronate-2-sulfatase - Google Patents

Purification of iduronate-2-sulfatase

Info

Publication number
NZ703093A
NZ703093A NZ703093A NZ70309313A NZ703093A NZ 703093 A NZ703093 A NZ 703093A NZ 703093 A NZ703093 A NZ 703093A NZ 70309313 A NZ70309313 A NZ 70309313A NZ 703093 A NZ703093 A NZ 703093A
Authority
NZ
New Zealand
Prior art keywords
sulfatase
iduronate
purified recombinant
purification
seq
Prior art date
Application number
NZ703093A
Other languages
English (en)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Priority to NZ733366A priority Critical patent/NZ733366A/en
Publication of NZ703093A publication Critical patent/NZ703093A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ703093A 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase NZ703093A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ733366A NZ733366A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
NZ703093A true NZ703093A (en) 2017-08-25

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ733366A NZ733366A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ733366A NZ733366A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP3441398A1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596357A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA3008945A1 (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA202090044A1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY180287A (enExample)
NZ (3) NZ703093A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871A1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI553120B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8974791B2 (en) 2007-07-27 2015-03-10 Armagen Technologies, Inc. Methods and compositions for increasing α-L-iduronidase activity in the CNS
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
EP3505538B1 (en) 2016-08-25 2024-05-01 JCR Pharmaceuticals Co., Ltd. Method for producing antibody fusion protein
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
ES2972119T3 (es) 2018-08-10 2024-06-11 Alexion Pharma Inc Cicatrización ósea en implantes utilizando fosfatasa alcalina
WO2020132452A1 (en) * 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
JP2022523063A (ja) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド アフリベルセプトの属性、並びにその特性決定及び修飾方法
KR20220111693A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제 폴리펩티드 및 이의 이용 방법
US20240052327A1 (en) * 2020-10-23 2024-02-15 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
EP1179000A4 (en) 1999-02-26 2005-10-12 Millennium Pharm Inc DECISION PROTEINS AND THEIR USE
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
AU2001252917A1 (en) 2000-03-17 2001-10-03 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP1276856A4 (en) 2000-04-12 2004-06-09 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
EP1575998A4 (en) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
HUE027210T2 (en) 2003-02-11 2016-10-28 Shire Human Genetic Therapies Cells expressing the enzyme producing sulfatase and C-formylglycine together and their uses
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
JP2009530378A (ja) 2006-03-20 2009-08-27 メダレックス インコーポレーティッド タンパク質精製法
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
JP5687069B2 (ja) * 2008-01-18 2015-03-18 バイオマリン ファーマシューティカル インコーポレイテッド 高度にリン酸化された活性なヒトリソソームスルファターゼ酵素の製造およびそれの使用
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
IL284599B2 (en) 2010-06-25 2024-02-01 Shire Human Genetic Therapies Methods and preparations for administration of iduronate-2-sulfatase to the central nervous system
US20110318327A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2623118A4 (en) 2010-09-28 2014-05-07 Kyoritsu Seiyaku Corp MUCOSAL ADJUVANT COMPOSITION
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
LT2867245T (lt) 2018-11-12
GT201400303A (es) 2017-08-31
CN107596358A (zh) 2018-01-19
UA129561C2 (uk) 2025-06-04
CN104583225A (zh) 2015-04-29
IL287057A (en) 2021-12-01
US12359178B2 (en) 2025-07-15
PT2867245T (pt) 2018-11-26
UA121959C2 (uk) 2020-08-25
RS58005B1 (sr) 2019-02-28
JP7594365B2 (ja) 2024-12-04
CL2014003567A1 (es) 2015-04-24
SG10201703489VA (en) 2017-05-30
US20240401010A1 (en) 2024-12-05
MX2015000190A (es) 2015-04-08
AU2018200230A1 (en) 2018-02-01
BR112014032567A2 (pt) 2017-08-01
AU2016200469A1 (en) 2016-02-18
KR20200143339A (ko) 2020-12-23
EP2867245A2 (en) 2015-05-06
US9492511B2 (en) 2016-11-15
IL236315A0 (en) 2015-02-26
KR20140002451A (ko) 2014-01-08
MX2019008914A (es) 2019-09-26
TW201410868A (zh) 2014-03-16
AU2013282395A1 (en) 2015-01-29
KR20140004603A (ko) 2014-01-13
US20240043817A1 (en) 2024-02-08
PH12015502408A1 (en) 2018-03-26
KR101380740B1 (ko) 2014-04-11
IL287057B1 (en) 2026-01-01
US20170073652A1 (en) 2017-03-16
PH12014502871B1 (en) 2015-02-23
EP2867245A4 (en) 2016-03-09
JP6171007B2 (ja) 2017-07-26
AU2018200230B2 (en) 2020-01-02
BR112014032567B1 (pt) 2022-09-13
JP6505629B2 (ja) 2019-04-24
JP2020105209A (ja) 2020-07-09
PE20150720A1 (es) 2015-05-16
WO2014005014A2 (en) 2014-01-03
CY1121519T1 (el) 2020-05-29
IL261264A (en) 2018-10-31
MY157087A (en) 2016-04-19
US10344270B2 (en) 2019-07-09
HUE040769T2 (hu) 2019-03-28
IL248727A0 (en) 2017-01-31
TWI587869B (zh) 2017-06-21
WO2014005014A3 (en) 2014-02-27
TWI553120B (zh) 2016-10-11
AU2013282395C1 (en) 2016-03-24
HRP20181897T1 (hr) 2019-01-11
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
US20150313972A1 (en) 2015-11-05
MY180287A (en) 2020-11-27
PL2867245T3 (pl) 2019-02-28
PH12020500027A1 (en) 2021-03-15
AR091647A1 (es) 2015-02-18
US20140004096A1 (en) 2014-01-02
JP2015523072A (ja) 2015-08-13
TR201815811T4 (tr) 2018-11-21
PH12014502871A1 (en) 2015-02-23
JP2016119911A (ja) 2016-07-07
DK2867245T3 (en) 2018-11-26
JP2018121645A (ja) 2018-08-09
SMT201800612T1 (it) 2019-01-11
MX366906B (es) 2019-07-30
CA2877517C (en) 2018-07-31
US9051556B2 (en) 2015-06-09
MX336715B (es) 2016-01-28
ZA201803289B (en) 2021-04-28
EA201492177A1 (ru) 2015-06-30
US20190359958A1 (en) 2019-11-28
MY192068A (en) 2022-07-25
HK1249027A1 (zh) 2018-10-26
US20210317426A1 (en) 2021-10-14
SG11201408761VA (en) 2015-01-29
PH12015502408B1 (en) 2020-02-14
NZ743910A (en) 2019-12-20
KR20220002227A (ko) 2022-01-06
CA3008945A1 (en) 2014-01-03
HK1209431A1 (en) 2016-04-01
TW201703794A (zh) 2017-02-01
CO7240396A2 (es) 2015-04-17
EA034549B1 (ru) 2020-02-19
IL261264B (en) 2021-10-31
ZA201409397B (en) 2019-10-30
DOP2014000294A (es) 2015-03-15
NZ733366A (en) 2019-12-20
ES2689468T3 (es) 2018-11-14
IL236315A (en) 2016-11-30
US11530393B2 (en) 2022-12-20
CA2877517A1 (en) 2014-01-03
KR20190064542A (ko) 2019-06-10
AU2016200469B2 (en) 2017-10-12
MX393364B (es) 2025-03-19
CN107596357A (zh) 2018-01-19
SI2867245T1 (sl) 2018-12-31
EA202090044A1 (ru) 2020-07-31
EP2867245B1 (en) 2018-09-12
EP3441398A1 (en) 2019-02-13
HK1249026A1 (zh) 2018-10-26
AU2013282395B2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
NZ703093A (en) Purification of iduronate-2-sulfatase
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
IN2012DN00801A (enExample)
SG191069A1 (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
IN2012DN00338A (enExample)
WO2013151672A3 (en) Modified polynucleotides for the production of oncology-related proteins and peptides
WO2009087082A3 (de) Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
NZ599774A (en) Melanocortin-1 receptor-specific cyclic peptides
NZ603811A (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
WO2013000922A9 (en) Ccr2 antagonist peptides
IN2014DN07017A (enExample)
BR112013010522A2 (pt) método para purificação de fator estimulador de colônias de granulócitos humano a partir recombinantes de e. coli
EA201300876A1 (ru) Мутантная целлобиогидролаза
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
PH12015500771A1 (en) Novel fc gamma receptor iib variants
NZ601142A (en) Composition for improving brain function and method for improving brain function
IN2014DN09367A (enExample)
MX351353B (es) Composiciones farmacéuticas basadas en shk y métodos para prepararlas y usarlas.
EA033091B1 (ru) ПШЕНИЦА С НОВЫМИ АЛЛЕЛЯМИ Rht-B1
AU2014370874A1 (en) Improved beta-fructofuranosidase
IN2012DN03358A (enExample)
MX2010010177A (es) Fragmentos de beta timosina mejorada.
WO2012031103A3 (en) Inhibitors of bcl-2
MX2010011055A (es) Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2019 BY ANAQUA SERVICES

Effective date: 20180522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2020 BY ANAQUA SERVICES

Effective date: 20190521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250521